ACADIA PHARMACEUTICALS INC. - 10-Q Summary (Q1 2026)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on neurological and rare diseases. Its core commercial products are NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. In December 2025, the FDA approved DAYBUE STIX, a new powder formulation, which began limited availability in Q1 2026 with a broader launch planned for Q2 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $268.1 million | $244.3 million |
| Net Income | $3.6 million | $19.0 million |
| Diluted EPS | $0.02 | $0.11 |
| Operating Cash Flow | $34.0 million | $20.3 million |
| Cash & Investments | $851.5 million | $819.7 million (Dec 31, 2025) |
| Accumulated Deficit | ($1.81 billion) | ($2.19 billion) |
Revenue Breakdown: NUPLAZID sales were $166.9 million; DAYBUE sales were $101.1 million.
Expenses: Total operating expenses were $272.7 million, driven by Selling, General, and Administrative (SG&A) expenses of $171.0 million and Research and Development (R&D) expenses of $76.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 9.7% year-over-year, driven by unit sales growth in both NUPLAZID (+4.5%) and DAYBUE (+19.6%).
- Profitability Decline: Net income decreased significantly to $3.6 million from $19.0 million in Q1 2025. This was primarily due to a 35% increase in SG&A expenses ($171.0M vs $126.4M) to support commercial growth, partially offset by a slight decrease in R&D expenses.
- Effective Tax Rate: The effective tax rate dropped to 8.6% in Q1 2026 from 31.6% in Q1 2025, largely due to low pre-tax income amplifying the impact of discrete tax items.
- Investing Activities: Net cash provided by investing activities turned positive ($66.3 million) compared to a net use of $124.0 million in the prior year, driven by maturities of investment securities and the absence of a $98.8 million milestone payment to Neuren made in Q1 2025.
Outlook, Risks, and Contingencies
- Regulatory Risks: In February 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Marketing Authorization Application (MAA) for trofinetide (DAYBUE) in the EU. Acadia requested a re-examination, but approval remains uncertain.
- Legal Proceedings:
- Patent Litigation: Acadia won final judgments against MSN and Aurobindo regarding NUPLAZID patent infringement in June 2025; defendants have appealed to the Federal Circuit.
- Securities Litigation: A securities class action regarding the sNDA for dementia-related psychosis is proceeding; pretrial motions were heard in April 2026. A derivative suit was settled in principle in January 2026 for $1.5 million in attorney fees.
- Supply Chain & Trade: The company faces risks from international trade policies, including potential tariffs on pharmaceutical ingredients from China, which could increase costs and disrupt supply chains.
- Liquidity: Management expects current cash, investments, and product sales to fund operations through and beyond the next 12 months.
Investor Verification Checklist
- EU Approval Status: Monitor the outcome of the re-examination of the CHMP negative opinion for trofinetide in the EU.
- SG&A Efficiency: Verify if the significant increase in SG&A expenses ($44.6M increase YoY) yields proportional revenue growth in subsequent quarters.
- Patent Appeals: Track the Federal Circuit appeals regarding NUPLAZID patent infringement cases against MSN and Aurobindo.
- DAYBUE STIX Launch: Assess the commercial uptake of the new DAYBUE STIX formulation following its broader launch in Q2 2026.
- Trade Policy Impact: Evaluate the potential financial impact of proposed tariffs on imported pharmaceutical ingredients on future cost of goods sold.